IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses

Sota, Yoshiaki; Seno, Shigeto; Naoi, Yasuto; Honma, Keiichiro; Shimoda, Masafumi; Tanei, Tomonori; Matsuda, Hideo; Shimazu, Kenzo

doi:https://doi.org/10.1007/s12282-025-01687-6

IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses

Sota, Yoshiaki; Seno, Shigeto; Naoi, Yasuto et al.

Breast Cancer, 2025

Number of Access:1,064（2025-08-13 23:45 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/101009

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
BreastCancer	pdf	None	2.44 MB	31	2025.04.17

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses
Creator	CreatorName Sota, Yoshiaki
	NRID 1000030432462 1000030432462 ORCID 0000-0003-3861-6444 0000-0003-3861-6444 researchmap permalink ssenoo ssenoo Scopus Author ID 57214748425 57214748425 CreatorName Seno, Shigeto
	NRID 1000030646211 1000030646211 CreatorName Naoi, Yasuto
	NRID 1000020505945 1000020505945 CreatorName Honma, Keiichiro
	NRID 1000030644455 1000030644455 ORCID 0000-0002-0832-9877 0000-0002-0832-9877 researchmap permalink shimodam shimodam Scopus Author ID 55796822600 55796822600 CreatorName Shimoda, Masafumi
	NRID 1000080771518 1000080771518 ORCID 0000-0003-2183-8681 0000-0003-2183-8681 researchmap permalink tanei tanei Scopus Author ID 6506192669 6506192669 CreatorName Tanei, Tomonori
	NRID 1000050183950 1000050183950 CreatorName Matsuda, Hideo
	NRID 1000030448039 1000030448039 researchmap permalink _-23f _-23f Scopus Author ID 7005224756 7005224756 CreatorName Shimazu, Kenzo
Subject	Breast cancer
	Immune signature
	Intrinsic subtype
	Neoadjuvant chemotherapy
	Pathological complete response
Description	The version of record of this article, first published in Breast Cancer, is available online at Publisher’s website: https://doi.org/10.1007/s12282-025-01687-6
Abstract	Background: This study evaluates the reproducibility of the IRSN-23 model, which classifies patients into highly chemotherapy-sensitive (Gp-R) or less-sensitive (Gp-NR) groups based on immune-related gene expression using DNA microarray analysis, and its impact on breast cancer subtype classification. Methods: Tumor tissues from 146 breast cancer patients receiving neoadjuvant chemotherapy (paclitaxel-FEC) ± trastuzumab at Osaka University Hospital (OUH) were used to classify patients into Gp-R or Gp-NR using IRSN-23. The ability to predict a pathological complete response (pCR) was assessed and the results were validated with independent public datasets (N = 1282). Results: In the OUH dataset, the pCR rate was significantly higher in the Gp-R group than in the Gp-NR group without trastuzumab (29 versus 1%, P = 1.70E−5). In all validation sets without anti-HER2 therapy, the pCR rate in the Gp-R group was significantly higher than that in the Gp-NR group. The pooled analysis of the validation set showed higher pCR rates in the Gp-R group than in the Gp-NR group, both without (N = 1103, 40 versus 12%, P = 2.02E−26) and with (N = 304, 49 versus 35%, P = 0.017) anti-HER2 therapy. Collaboration analyses of IRSN-23 and Oncotype Dx or PAM50 could identify highly chemotherapy-sensitive groups and refine breast cancer subtype classification based on the tumor microenvironment (offensive factor—PAM50 and defensive factor—IRSN-23), and the immune subtype was correlated with a better prognosis after NAC. Conclusions: This study offers new validation analyses of IRSN-23 in predicting chemotherapy efficacy, showing high reproducibility. The findings indicate the clinical value of using IRSN-23 for refining breast cancer subtype classification, with implications for personalized treatment strategies and improved patient outcomes.
Publisher	Springer
Source Title	Breast Cancer
Date of Issued	2025-03-24
Language	English
Handle URL	https://hdl.handle.net/11094/101009
PISSN	13406868
eISSN	18804233
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1007/s12282-025-01687-6
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCTERMS.bibliographicCitation	Breast Cancer. 2025
DC.title	IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses
DC.creator	Sota, Yoshiaki
	Seno, Shigeto
	Naoi, Yasuto
	Honma, Keiichiro
	Shimoda, Masafumi
	Tanei, Tomonori
	Matsuda, Hideo
	Shimazu, Kenzo
DC.publisher	Springer
DC.language' scheme='DCTERMS.RFC1766	English
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-03-24
DC.identifier	https://doi.org/10.1007/s12282-025-01687-6
DC.subject	Breast cancer
	Immune signature
	Intrinsic subtype
	Neoadjuvant chemotherapy
	Pathological complete response
DC.description	The version of record of this article, first published in Breast Cancer, is available online at Publisher’s website: https://doi.org/10.1007/s12282-025-01687-6
DCTERMS.abstract	Background: This study evaluates the reproducibility of the IRSN-23 model, which classifies patients into highly chemotherapy-sensitive (Gp-R) or less-sensitive (Gp-NR) groups based on immune-related gene expression using DNA microarray analysis, and its impact on breast cancer subtype classification. Methods: Tumor tissues from 146 breast cancer patients receiving neoadjuvant chemotherapy (paclitaxel-FEC) ± trastuzumab at Osaka University Hospital (OUH) were used to classify patients into Gp-R or Gp-NR using IRSN-23. The ability to predict a pathological complete response (pCR) was assessed and the results were validated with independent public datasets (N = 1282). Results: In the OUH dataset, the pCR rate was significantly higher in the Gp-R group than in the Gp-NR group without trastuzumab (29 versus 1%, P = 1.70E−5). In all validation sets without anti-HER2 therapy, the pCR rate in the Gp-R group was significantly higher than that in the Gp-NR group. The pooled analysis of the validation set showed higher pCR rates in the Gp-R group than in the Gp-NR group, both without (N = 1103, 40 versus 12%, P = 2.02E−26) and with (N = 304, 49 versus 35%, P = 0.017) anti-HER2 therapy. Collaboration analyses of IRSN-23 and Oncotype Dx or PAM50 could identify highly chemotherapy-sensitive groups and refine breast cancer subtype classification based on the tumor microenvironment (offensive factor—PAM50 and defensive factor—IRSN-23), and the immune subtype was correlated with a better prognosis after NAC. Conclusions: This study offers new validation analyses of IRSN-23 in predicting chemotherapy efficacy, showing high reproducibility. The findings indicate the clinical value of using IRSN-23 for refining breast cancer subtype classification, with implications for personalized treatment strategies and improved patient outcomes.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	101009
citation_title	IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses
citation_author	Sota, Yoshiaki
	Seno, Shigeto
	Naoi, Yasuto
	Honma, Keiichiro
	Shimoda, Masafumi
	Tanei, Tomonori
	Matsuda, Hideo
	Shimazu, Kenzo
citation_publisher	Springer
citation_language	English
citation_date	2025-03-24
citation_journal_title	Breast Cancer
citation_doi	https://doi.org/10.1007/s12282-025-01687-6
citation_public_url	https://hdl.handle.net/11094/101009

IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses

Link to primary information

Item Information

Show details